Merck & Co., Inc. (MRK) Price Target Raised to $78.00 at Barclays
The firm currently has an "overweight" rating on the stock. Barclays' price target indicates a potential upside of 11.73% from the company's previous close.
from Biotech News
The firm currently has an "overweight" rating on the stock. Barclays' price target indicates a potential upside of 11.73% from the company's previous close.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments